计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| A302849-250mg |
250mg |
现货 ![]() |
| |
| A302849-1g |
1g |
现货 ![]() |
| |
| A302849-5g |
5g |
现货 ![]() |
| |
| A302849-25g |
25g |
现货 ![]() |
|
| 别名 | N-[2-[[2-(二甲基氨基)乙基]甲基氨基]-4-甲氧基-5-[[4-(1-甲基-1H-吲哚-3-基)-2-嘧啶基]氨基]苯基]-2-丙烯酰胺 |
|---|---|
| 英文别名 | Mereletinib | AZD-9291 |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Osimertinib (AZD9291) |
| 储存温度 | 2-8°C储存,干燥 |
| 运输条件 | 冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 表皮生长因子受体 erbB1 抑制剂 |
| 产品介绍 |
Osimtinib (AZD9291) 是一种共价结合、不可逆和突变选择性的 EGFR 抑制剂,其有效抑制 L858R (IC50=12 nM) 和 L858R/T790M (IC50=1 nM) EGFR。Osimtinib 解决了肺癌 T790M 突变介导的 EGFR 抑制剂耐药。
Osimertinib (AZD9291) is a irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
|
| 纯度 | ≥99% |
| ALogP | 3.7 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504772142 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide |
| INCHI | 1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32) |
| InChi Key | DUYJMQONPNNFPI-UHFFFAOYSA-N |
| Smiles | CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC |
| Isomeric SMILES | CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC |
| 关联CAS | 1421373-65-0 |
| MeSH Entry Terms | AZD-9291;AZD-9291 mesylate;AZD9291;AZD9291 mesylate;mereletinib;mereletinib mesilate;mereletinib mesylate;N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide;N-(2-((2-(dimethylamino |
| 分子量 | 499.62 |
| Reaxy-Rn | 23334373 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=23334373&ln= |
| 溶解性 | ≥24.98 mg/mL in DMSO; insoluble in H2O; ≥8.09 mg/mL in EtOH with ultrasonic |
|---|---|
| 分子量 | 499.600 g/mol |
| XLogP3 | 3.700 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 7 |
| 可旋转键计数Rotatable Bond Count | 10 |
| 精确质量Exact Mass | 499.27 Da |
| 单同位素质量Monoisotopic Mass | 499.27 Da |
| 拓扑极表面积Topological Polar Surface Area | 87.600 Ų |
| 重原子数Heavy Atom Count | 37 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 752.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 | |
| 分析证书 | A302849 |
¥259.90
| 1. Yu HA, Riely GJ. (2013) Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.. J Natl Compr Canc Netw, 11 (2): (161-9). [PMID:23411383] |
| 2. Ou SH, Soo RA. (2015) Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?. Drug Des Devel Ther, 9 (5641-53). [PMID:26508839] |
| 3. Song HN, Jung KS, Yoo KH, Cho J, Lee JY, Lim SH, Kim HS, Sun JM, Lee SH, Ahn JS et al.. (2016) Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.. J Thorac Oncol, 11 (4): (e45-7). [PMID:26749488] |
| 4. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ et al.. (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.. Cancer Discov, 4 (9): (1046-61). [PMID:24893891] |
| 5. Wang S, Cang S, Liu D. (2016) Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.. J Hematol Oncol, 9 (34). [PMID:27071706] |
| 6. Bersanelli M, Minari R, Bordi P, Gnetti L, Bozzetti C, Squadrilli A, Lagrasta CA, Bottarelli L, Osipova G, Capelletto E et al.. (2016) L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.. J Thorac Oncol, 11 (10): (e121-3). [PMID:27257132] |
| 7. Yu HA, Tian SK, Drilon AE, Borsu L, Riely GJ, Arcila ME, Ladanyi M. (2015) Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.. JAMA Oncol, 1 (7): (982-4). [PMID:26181354] |
| 8. Xin Zhang, Yuhan Jiang, Na Guo, Yifan Ding, Jingting Feng, Chenyang Miao, Yanni Lv. (2023) Application of SNAP-tag-EGFR cell membrane chromatography model in screening antitumor active components of Silybum marianum (L.) Gaertn. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, (115816). [PMID:37976988] [10.1016/j.jpba.2023.115816] |
| 9. Zihan Zhu, Peigang Zhang, Kexin An, Kaihua Zhao, Xianghui Chen, Yuheng Pei, Martin M. F. Choi, Ning Wang, Wei Bian. (2023) pH/hyaluronidase dual responsive nano drug delivery systems for photothermal/chemotherapy combined treatment for non-small cell lung cancer. NEW JOURNAL OF CHEMISTRY, 47 (46): (21175-21182). [10.1039/D3NJ03075J] |
| 10. Dianbao Zhang, Yukun Yang, Yixin Kang, Dongjie Xie, Xianfen Zhang, Jiqing Hao. (2023) Dysregulated expression of microRNA involved in resistance to osimertinib in EGFR mutant non-small cell lung cancer cells. Journal of Thoracic Disease, 15 (4): ( 1978–1993). [PMID:37197540] [10.21037/jtd-23-401] |
| 11. Taotao Huo, Bin Zhu, Xiaoyu Shan, Jiaqi Song, Ziyi Wang, Jianxu Zhou, Xianpeng Zhang, Yuquan Bai, Chengcheng Liu, Yiyang Zhao, Na Mei, Yazhong Bu, Jia Zhang, Guangying Li. (2025) Allicin amplifies disulfidptosis during GOx catalyzing glucose-starvation for cancer therapy via simultaneous antimicrobial and antitumor intervention. CHEMICAL ENGINEERING JOURNAL, 505 (159871). [10.1016/j.cej.2025.159871] |
| 12. Rui Feng, Yong-Qi Zhen, Dongbo Wu, Lian Sun, Jin-Bu Xu, Xiaohuan Li, Lan Zhang, Feng Gao. (2024) Late-stage modification of complex drug: Base-controlled Pd-catalyzed regioselective synthesis and bioactivity of arylated osimertinibs. Science Advances, 10 (10): [PMID:38457511] [10.1126/sciadv.adl0026] |